AMLX
Amylyx Pharmaceuticals Inc
27.80$
-1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -100.0% | – | – | -100.0% | – | – | – | +6,243.5% | +226.4% | +37.5% | +4.6% | +5.6% | -18.3% | -101.2% | – | -259.9% | – | – | – | – | – | – | – | |
| – | +36.9% | +59.2% | +17.6% | +4.2% | +60.3% | -99.5% | +63.8% | +1,540.1% | +87.3% | +5.6% | -6.5% | +79.4% | +1,143.7% | -93.4% | -89.4% | -80.2% | +13,724.4% | -99.4% | +13,981.6% | -99.5% | -9.3% | – | – | |
| – | – | – | – | – | – | – | – | +10,919.7% | +247.0% | +40.0% | +5.2% | +1.7% | -128.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +36.9% | +59.2% | +17.6% | +4.2% | +60.3% | +13.0% | +2.7% | -8.4% | +6.0% | +20.1% | +3.4% | +49.5% | -18.5% | -36.8% | -8.2% | +7.8% | -3.4% | +22.4% | -26.7% | +6.3% | +30.8% | -13.9% | – | |
| – | +52.8% | +27.5% | +35.2% | +132.0% | +9.7% | +13.8% | -0.2% | +88.2% | -21.9% | -1.4% | +12.3% | -12.3% | +35.1% | -62.5% | -17.6% | -19.2% | +8.9% | -0.3% | +3.4% | -4.8% | +5.0% | +35.6% | – | |
| – | -30.1% | +27.5% | +199.3% | -34.9% | +76.6% | +105.9% | +1.1% | +16.0% | +7.1% | +6.2% | +8.7% | +23.4% | -2.9% | -52.5% | +68.1% | -46.9% | -60.8% | +172.4% | -62.1% | +125.7% | +20.0% | +4.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | -7.3% | -89.7% | -6,414.9% | – | – | – | – | – | – | – | – | – | – | |
| – | +100.0% | -50.0% | +200.0% | +900.0% | +336.7% | +206.9% | +49.5% | +425.3% | +9.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +1,611.1% | -6.6% | -71.1% | -1,930.6% | – | – | – | – | – | – | – | – | – | – | |
| – | +82,550.0% | +101.7% | -93.4% | -113.6% | – | +19.2% | -171.8% | – | -129.4% | – | -21.5% | +15.0% | -86.1% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +1,303.3% | -5.4% | -77.4% | -2,610.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +1,411.4% | -6.5% | -70.2% | -1,844.7% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.